SCHEMBL19689567

SCHEMBL19689567

CC(C)(C)OC(=O)N1CC(O)(c2ccc(O)cc2Cl)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.53
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NR1H2 P55055 2/20 0.38
POLB P06746 1/20 0.37
STS P08842 4/20 0.37
PDK2 Q15119 1/20 0.36
F13A1 P00488 1/20 0.35
TGM2 P21980 1/20 0.35
TGM1 P22735 1/20 0.35
TGM3 Q08188 1/20 0.35
MET P08581 1/20 0.35
AXL P30530 1/20 0.35
HDAC1 Q13547 1/20 0.35
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
OXTR P30559 1/20 0.35
AVPR1A P37288 1/20 0.35
ABHD6 Q9BV23 1/20 0.34
HTR6 P50406 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29735795 1.00 ESR2 (0.53) ESR2MEN1KMT2ANR1H2POLB
SCHEMBL31735017 0.86 RORC (0.42) ESR2MEN1KMT2ANR1H2POLB
SCHEMBL19202540 0.85 ALDH1A1 (0.43) ESR2MEN1KMT2ASTSMET
SCHEMBL15689748 0.83 STS (0.44) ESR2MEN1KMT2APOLBSTS
SCHEMBL19705736 0.81 ESR2 (0.38) ESR2MEN1KMT2ANR1H2POLB
SCHEMBL19689482 0.80 MET (0.37) ESR2MEN1KMT2ANR1H2POLB
SCHEMBL29736070 0.80 MET (0.37) ESR2MEN1KMT2ANR1H2POLB
SCHEMBL19718048 0.79 HSD17B10 (0.37) ESR2MEN1KMT2AABHD6DRD2
SCHEMBL31559760 0.78 STS (0.47) ESR2MEN1KMT2APOLBSTS
SCHEMBL31401551 0.78 KMT2A (0.43) ESR2MEN1KMT2ANR1H2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055094-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2026-02-26 US disclosed
EP-4691553-A2 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2026-02-11 EP disclosed
US-12358903-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2025-07-15 US disclosed
EP-4534536-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2025-04-09 EP disclosed
US-20250026744-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2025-01-23 US disclosed
EP-4089072-B1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2024-08-28 EP disclosed
EP-4360632-A2 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2024-05-01 EP disclosed
CN-117924266-A Compounds that modulate FXR (NR 1H 4) 吉利德科学公司 2024-04-26 CN disclosed
CN-117924267-A Compounds that modulate FXR (NR 1H 4) 吉利德科学公司 2024-04-26 CN disclosed
CN-109476636-B Compounds that modulate FXR (NR 1H 4) 吉利德科学公司 2024-01-09 CN disclosed
WO-2017218337-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2017-12-21 WO disclosed
WO-2017218330-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2017-12-21 WO disclosed
WO-2017218330-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2017-12-21 WO disclosed
EP-3257847-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2017-12-20 EP disclosed
EP-3257847-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2017-12-20 EP disclosed
US-20170355685-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed
US-20170355685-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed
US-20170355693-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed
US-20170355693-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed
US-20170355693-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026744-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 ESR2 71/4885MEN1 4469/4885KMT2A 3234/4885
US-12358903-B2 FXR (NR1H4) modulating compounds NR1H4, NR1H2, NR1H3 ESR2 77/4885MEN1 4302/4885KMT2A 3361/4885
US-20170355685-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 ESR2 77/4885MEN1 4302/4885KMT2A 3361/4885
US-20260055094-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 ESR2 124/4885MEN1 3621/4885KMT2A 3049/4885
US-20170355693-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 ESR2 77/4885MEN1 4302/4885KMT2A 3361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.